Akari Therapeutics (AKTX) Gains from Sales and Divestitures (2023 - 2026)

Akari Therapeutics has disclosed Gains from Sales and Divestitures across 4 years of filings, most recently posting $1465.0 for Q1 2026.

• Gains from Sales and Divestitures for Q1 2026 came in at $1465.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1465.0 (changed N/A YoY), and the FY2025 annual result was $46277.0, down 99.99% from the prior year.
• Gains from Sales and Divestitures came in at $1465.0 for Q1 2026 at Akari Therapeutics, down from $46277.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $635.1 million in Q4 2024 to a low of $1465.0 in Q1 2026.
• The 4-year median for Gains from Sales and Divestitures is $43.4 million (2023), against an average of $171.4 million.
• Across the five-year window, Gains from Sales and Divestitures surged 1364.6% in 2024 and slumped 99.99% in 2025, its largest moves.
• Akari Therapeutics' Gains from Sales and Divestitures stood at $43.4 million in 2023, then soared by 1364.6% to $635.1 million in 2024, then plunged by 99.99% to $46277.0 in 2025, then plunged by 96.83% to $1465.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $1465.0 (Q1 2026), $46277.0 (Q4 2025), and $40000.0 (Q3 2025), per Business Quant data.